Skip to main navigation Skip to search Skip to main content

How do I: Evaluate the safety and legitimacy of unproven cellular therapies?

  • Indira Guleria
  • , Maria de Los Angeles Muñiz
  • , Matthew Wilgo
  • , Asawari Bapat
  • , Wanxing Cui
  • , Yen Michael Sheng Hsu
  • , Madhan Jeyaraman
  • , Sathish Muthu
  • , Federico Rodriguez
  • , Andrew Fesnak
  • , Christina Celluzzi
  • , Deborah Sesok-Pizzini
  • , Ronit Reich-Slotky
  • , Thomas Spitzer
  • Brigham and Women's Hospital
  • Harvard University
  • Cornell University
  • New England Cryogenic Center. Inc.
  • Infohealth FZE
  • MedStar Georgetown University Hospital
  • University of Pittsburgh
  • Sri Lalithambigai Medical College and Hospital
  • Sharda University
  • Government Medical College and Hospital
  • University of Florida
  • University of Pennsylvania
  • Association for the Advancement of Blood and Biotherapies
  • Rutgers - The State University of New Jersey, Newark
  • Massachusetts General Hospital

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Background: Unproven cellular therapies are being offered to patients for a variety of conditions and diseases for which other treatments have failed. The use of untested cellular therapies is a worldwide problem. Practitioners (e.g., physicians, scientists, QA/QI facility managers, and policy advocates) are perhaps unaware of the risks involved with such therapies. Therefore, a critical need exists to bring attention to the potential limitations and adverse effects of these therapies to inform and limit misinformation. Study Design and Methods: We describe the extent of the unproven cellular therapy problem through a search of scientific literature and social media coverage. We also describe the regulatory framework that can be used by the practitioner to review and evaluate both proven and unproven cellular therapies. Results: We report on the current state of unproven cellular therapies across the globe. A workflow to facilitate an understanding of the regulatory processes involved in the approval of cellular therapies is provided as well as a list of warnings required by regulatory agencies on various products. It is hoped that this article will serve as a tool kit to educate the practitioner on navigating the field of unproven cellular therapy products. Discussion: Increasing awareness of the issues associated with unproven therapies through education is important to help in reducing misinformation and risks to patients.

Original languageEnglish
Pages (from-to)518-532
Number of pages15
JournalTransfusion
Volume62
Issue number3
DOIs
StatePublished - Mar 2022
Externally publishedYes

Keywords

  • adverse events
  • biological products
  • Food and Drug Administration (FDA)
  • hematopoietic stem cells
  • investigational new drug application (IND)
  • regulatory agencies
  • stem cell tourism
  • toolkit
  • unapproved cellular therapies
  • unproven cellular therapies

Fingerprint

Dive into the research topics of 'How do I: Evaluate the safety and legitimacy of unproven cellular therapies?'. Together they form a unique fingerprint.

Cite this